Cita APA (7a ed.)
Soumerai, J., Wang, L., Gu, F., Gu, T., & Liu, F. F. (Jun2023 Supplement S2). REAL‐WORLD OUTCOMES OF PATIENTS (PT) WITH RELAPSED OR REFRACTORY (R/R) CLL/SLL AND PRIOR TREATMENT (TX) WITH BOTH A BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND VENETOCLAX. Hematological Oncology, 41, 733-735.
Cita Chicago Style (17a ed.)
Soumerai, J., L. Wang, F. Gu, T. Gu, y F. F. Liu. "REAL‐WORLD OUTCOMES OF PATIENTS (PT) WITH RELAPSED OR REFRACTORY (R/R) CLL/SLL AND PRIOR TREATMENT (TX) WITH BOTH A BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND VENETOCLAX." Hematological Oncology 41 (Jun2023 Supplement S2): 733-735.
Cita MLA (9a ed.)
Soumerai, J., et al. "REAL‐WORLD OUTCOMES OF PATIENTS (PT) WITH RELAPSED OR REFRACTORY (R/R) CLL/SLL AND PRIOR TREATMENT (TX) WITH BOTH A BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND VENETOCLAX." Hematological Oncology, vol. 41, Jun2023 Supplement S2, pp. 733-735.
Precaución: Estas citas no son 100% exactas.